Caffeic acid phenethyl ester as a potential treatment for advanced prostate cancer targeting Akt signaling

International Journal of Molecular Sciences

Volumn 14, Issue 3, 2013, Pages 5264-5283

  Lin, Hui Ping ^a   Lin, Ching Yu ^a   Liu, Chun Chieh ^b,c,d   Su, Liang Cheng ^a   Huo, Chieh ^a,e   Kuo, Ying Yu ^a   Tseng, Jen Chih ^a,f   Hsu, Jong Ming ^b   Chen, Chi Kuan ^b   Chuu, Chih Pin ^a,g,h  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^e NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^f NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Akt; Caffeic acid phenethyl ester; LNCaP; PC 3; Prostate cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CAFFEIC ACID PHENETHYL ESTER; ESTRAMUSTINE; ETOPOSIDE; MITOXANTRONE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BRAIN INJURY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; COLON METASTASIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; GENE DELETION; HEART INJURY; HUMAN; KIDNEY INJURY; LIVER CANCER; LIVER METASTASIS; LIVER TOXICITY; LUNG FIBROSIS; LUNG INJURY; MELANOMA; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; RADIATION INJURY; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY;

EID: 84875083185     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14035264     Document Type: Review

References (132)

1. Karan, D.; Thrasher, J.B.; Lubaroff, D. Prostate cancer: Genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis. 2008, 11, 230-236.
2. Kuriyama, M.; Wang, M.C.; Lee, C.I.; Papsidero, L.D.; Killian, C.S.; Inaji, H.; Slack, N.H.; Nishiura, T.; Murphy, G.P.; Chu, T.M. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981, 41, 3874-3876.
3. Nadji, M.; Tabei, S.Z.; Castro, A.; Chu, T.M.; Murphy, G.P.; Wang, M.C.; Morales, A.R. Prostatic-Specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 1981, 48, 1229-1232.
4. Riegman, P.H.; Vlietstra, R.J.; van der Korput, J.A.; Brinkmann, A.O.; Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 1991, 5, 1921-1930.
5. Wolf, D.A.; Schulz, P.; Fittler, F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol. Endocrinol. 1992, 6, 753-762.
6. Feldman, B.J.; Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1, 34-45.
7. Ricke, E.A.; Williams, K.; Lee, Y.F.; Couto, S.; Wang, Y.; Hayward, S.W.; Cunha, G.R.; Ricke, W.A. Androgen hormone action in prostatic carcinogenesis: Stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis 2012, 33, 1391-1398.
8. Chuu, C.P.; Kokontis, J.M.; Hiipakka, R.A.; Fukuchi, J.; Lin, H.P.; Lin, C.Y.; Huo, C.; Su, L.C. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J. Biomed. Sci 2011, 18, 63.
9. Chuu, C.P.; Hiipakka, R.A.; Fukuchi, J.; Kokontis, J.M.; Liao, S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005, 65, 2082-2084.
10. Chuu, C.P.; Hiipakka, R.A.; Kokontis, J.M.; Fukuchi, J.; Chen, R.Y.; Liao, S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 2006, 66, 6482-6486.
11. Chuu, C.P.; Kokontis, J.M.; Hiipakka, R.A.; Fukuchi, J.; Lin, H.P.; Lin, C.Y.; Huo, C.; Su, L.C.; Liao, S. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci. 2011, 102, 2022-2028.
12. Wang, Q.; Li, W.; Liu, X.S.; Carroll, J.S.; Janne, O.A.; Keeton, E.K.; Chinnaiyan, A.M.; Pienta, K.J.; Brown, M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell. 2007, 27, 380-392.
13. Xu, Y.; Chen, S.Y.; Ross, K.N.; Balk, S.P. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006, 66, 7783-7792.
14. Wang, Q.; Li, W.; Zhang, Y.; Yuan, X.; Xu, K.; Yu, J.; Chen, Z.; Beroukhim, R.; Wang, H.; Lupien, M., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009, 138, 245-256.
15. Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644-648.
16. Cerveira, N.; Ribeiro, F.R.; Peixoto, A.; Costa, V.; Henrique, R.; Jeronimo, C.; Teixeira, M.R. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8, 826-832.
17. Cai, C.; Wang, H.; Xu, Y.; Chen, S.; Balk, S.P. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009, 69, 6027-6032.
18. Van der Kwast, T.H.; Schalken, J.; Ruizeveld de Winter, J.A.; van Vroonhoven, C.C.; Mulder, E.; Boersma, W.; Trapman, J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 1991, 48, 189-193.
19. Ruizeveld de Winter, J.A.; Janssen, P.J.; Sleddens, H.M.; Verleun-Mooijman, M.C.; Trapman, J.; Brinkmann, A.O.; Santerse, A.B.; Schroder, F.H.; van der Kwast, T.H. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 1994, 144, 735-746.
20. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinanen, R.; Palmberg, C.; Palotie, A.; Tammela, T.; Isola, J.; Kallioniemi, O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9, 401-406.
21. Bubendorf, L.; Kononen, J.; Koivisto, P.; Schraml, P.; Moch, H.; Gasser, T.C.; Willi, N.; Mihatsch, M.J.; Sauter, G.; Kallioniemi, O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999, 59, 803-806.
22. Linja, M.J.; Savinainen, K.J.; Saramaki, O.R.; Tammela, T.L.; Vessella, R.L.; Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61, 3550-3555.
23. Ford, O.H., III; Gregory, C.W.; Kim, D.; Smitherman, A.B.; Mohler, J.L. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 2003, 170, 1817-1821.
24. Holzbeierlein, J.; Lal, P.; LaTulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164, 217-227.
25. Mohler, J.L.; Gregory, C.W.; Ford, O.H., III; Kim, D.; Weaver, C.M.; Petrusz, P.; Wilson, E.M.; French, F.S. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 2004, 10, 440-448.
26. Stanbrough, M.; Bubley, G.J.; Ross, K.; Golub, T.R.; Rubin, M.A.; Penning, T.M.; Febbo, P.G.; Balk, S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66, 2815-2825.
27. Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T., et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57, 314-319.
28. Brown, R.S.; Edwards, J.; Dogan, A.; Payne, H.; Harland, S.J.; Bartlett, J.M.; Masters, J.R Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 2002, 198, 237-244.
29. Edwards, J.; Krishna, N.S.; Grigor, K.M.; Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89, 552-556.
30. Sadar, M.D. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res. 2011, 71, 1208-1213.
31. Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch, M.J. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000, 31, 578-583.
32. Ibrahim, T.; Flamini, E.; Mercatali, L.; Sacanna, E.; Serra, P.; Amadori, D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116, 1406-1418.
33. Keller, E.T.; Zhang, J.; Cooper, C.R.; Smith, P.C.; McCauley, L.K.; Pienta, K.J.; Taichman, R.S. Prostate carcinoma skeletal metastases: Cross-Talk between tumor and bone. Cancer Metastasis Rev. 2001, 20, 333-349.
34. Huggins, C.; Stevens, R.; Hodges, C. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941, 43, 15.
35. Seruga, B.; Tannock, I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 2008, 5, 574-576.
36. Hellerstedt, B.A.; Pienta, K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002, 52, 154-179.
37. Gilligan, T.; Kantoff, P.W. Chemotherapy for prostate cancer. Urology 2002, 60, 94-100.
38. Pinto, A.C.; Moreira, J.N.; Simoes, S. Liposomal imatinib-mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate 2011, 71, 81-90.
39. Coffer, P.J.; Jin, J.; Woodgett, J.R. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 1998, 335, 1-13.
40. Gonzalez, E.; McGraw, T.E. The Akt kinases: Isoform specificity in metabolism and cancer. Cell. Cycle 2009, 8, 2502-2508.
41. Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 4240-4245.
42. Sarker, D.; Reid, A.H.; Yap, T.A.; de Bono, J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15, 4799-4805.
43. Bedolla, R.; Prihoda, T.J.; Kreisberg, J.I.; Malik, S.N.; Krishnegowda, N.K.; Troyer, D.A.; Ghosh, P.M. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 3860-3867.
44. Squire, J.A. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat. Genet. 2009, 41, 509-510.
45. King, J.C.; Xu, J.; Wongvipat, J.; Hieronymus, H.; Carver, B.S.; Leung, D.H.; Taylor, B.S.; Sander, C.; Cardiff, R.D.; Couto, S.S., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41, 524-526.
46. Carver, B.S.; Tran, J.; Gopalan, A.; Chen, Z.; Shaikh, S.; Carracedo, A.; Alimonti, A.; Nardella, C.; Varmeh, S.; Scardino, P.T., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41, 619-624.
47. Alessi, D.R.; James, S.R.; Downes, C.P.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7, 261-269.
48. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
49. Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S.Y.; Huang, Q.; Qin, J.; Su, B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006, 127, 125-137.
50. Hammarsten, P.; Cipriano, M.; Josefsson, A.; Stattin, P.; Egevad, L.; Granfors, T.; Fowler, C.J. Phospho-Akt immunoreactivity in prostate cancer: Relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 2012, 7, e47994.
51. Chuu, C.P.; Chen, R.Y.; Barkinge, J.L.; Ciaccio, M.F.; Jones, R.B. Systems-Level analysis of ErbB4 signaling in breast cancer: A laboratory to clinical perspective. Mol. Cancer Res. 2008, 6, 885-891.
52. Morgan, T.M.; Koreckij, T.D.; Corey, E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets 2009, 9, 237-249.
53. Dai, B.; Kong, Y.Y.; Ye, D.W.; Ma, C.G.; Zhou, X.; Yao, X.D. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2009, 104, 1009-1016.
54. Kreisberg, J.I.; Malik, S.N.; Prihoda, T.J.; Bedolla, R.G.; Troyer, D.A.; Kreisberg, S.; Ghosh, P.M. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004, 64, 5232-5236.
55. Sircar, K.; Yoshimoto, M.; Monzon, F.A.; Koumakpayi, I.H.; Katz, R.L.; Khanna, A.; Alvarez, K.; Chen, G.; Darnel, A.D.; Aprikian, A.G., et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 2009, 218, 505-513.
56. Wegiel, B.; Bjartell, A.; Culig, Z.; Persson, J.L. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int. J. Cancer 2008, 122, 1521-1529.
57. McCall, P.; Gemmell, L.K.; Mukherjee, R.; Bartlett, J.M.; Edwards, J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer 2008, 98, 1094-1101.
58. Shimizu, Y.; Segawa, T.; Inoue, T.; Shiraishi, T.; Yoshida, T.; Toda, Y.; Yamada, T.; Kinukawa, N.; Terada, N.; Kobayashi, T., et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int. 2007, 100, 685-690.
59. Ayala, G.; Thompson, T.; Yang, G.; Frolov, A.; Li, R.; Scardino, P.; Ohori, M.; Wheeler, T.; Harper, W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004, 10, 6572-6578.
60. Orio, F., Jr.; Terouanne, B.; Georget, V.; Lumbroso, S.; Avances, C.; Siatka, C.; Sultan, C. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol. Cell. Endocrinol. 2002, 198, 105-114.
61. Wang, Y.; Kreisberg, J.I.; Ghosh, P.M. Cross-Talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr. Cancer Drug Targets 2007, 7, 591-604.
62. Culig, Z.; Hobisch, A.; Cronauer, M.V.; Radmayr, C.; Trapman, J.; Hittmair, A.; Bartsch, G.; Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54, 5474-5478.
63. Fan, W.; Yanase, T.; Morinaga, H.; Okabe, T.; Nomura, M.; Daitoku, H.; Fukamizu, A.; Kato, S.; Takayanagi, R.; Nawata, H. Insulin-Like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J. Biol. Chem. 2007, 282, 7329-7338.
64. Nelson, E.C.; Evans, C.P.; Mack, P.C.; Devere-White, R.W.; Lara, P.N., Jr. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007, 10, 331-339.
65. Bhimani, R.S.; Troll, W.; Grunberger, D.; Frenkel, K. Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res. 1993, 53, 4528-4533.
66. Natarajan, K.; Singh, S.; Burke, T.R., Jr.; Grunberger, D.; Aggarwal, B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc. Natl. Acad. Sci. USA 1996, 93, 9090-9095.
67. Nomura, M.; Kaji, A.; Ma, W.; Miyamoto, K.; Dong, Z. Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester. Mol. Carcinog. 2001, 31, 83-89.
68. Wu, J.; Omene, C.; Karkoszka, J.; Bosland, M.; Eckard, J.; Klein, C.B.; Frenkel, K. Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. Cancer Lett. 2011, 308, 43-53.
69. Watabe, M.; Hishikawa, K.; Takayanagi, A.; Shimizu, N.; Nakaki, T. Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. J. Biol. Chem. 2004, 279, 6017-6026.
70. Chuu, C.P.; Lin, H.P.; Ciaccio, M.F.; Kokontis, J.M.; Hause, R.J., Jr.; Hiipakka, R.A.; Liao, S.; Jones, R.B. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. Cancer Prev. Res. (Phila) 2012, 5, 788-797.
71. Lin, H.P.; Jiang, S.S.; Chuu, C.P. Caffeic acid phenethyl ester causes p21 induction, Akt Signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS One 2012, 7, e31286.
72. McEleny, K.; Coffey, R.; Morrissey, C.; Fitzpatrick, J.M.; Watson, R.W. Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins. BJU Int. 2004, 94, 402-406.
73. Chen, M.F.; Wu, C.T.; Chen, Y.J.; Keng, P.C.; Chen, W.C. Cell killing and radiosensitization by caffeic acid phenethyl ester (CAPE) in lung cancer cells. J. Radiat. Res. (Tokyo) 2004, 45, 253-260.
74. Lin, H.P.; Kuo, L.K.; Chuu, C.P. Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. Phytother. Res. 2011, 26, 122-126.
75. Lee, Y.T.; Don, M.J.; Hung, P.S.; Shen, Y.C.; Lo, Y.S.; Chang, K.W.; Chen, C.F.; Ho, L.K. Cytotoxicity of phenolic acid phenethyl esters on oral cancer cells. Cancer Lett. 2005, 223, 19-25.
76. Onori, P.; DeMorrow, S.; Gaudio, E.; Franchitto, A.; Mancinelli, R.; Venter, J.; Kopriva, S.; Ueno, Y.; Alvaro, D.; Savage, J., et al. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int. J. Cancer J. Int. Cancer 2009, 125, 565-576.
77. Hung, M.W.; Shiao, M.S.; Tsai, L.C.; Chang, G.G.; Chang, T.C. Apoptotic effect of caffeic acid phenethyl ester and its ester and amide analogues in human cervical cancer ME180 cells. Anticancer Res. 2003, 23, 4773-4780.
78. Usia, T.; Banskota, A.H.; Tezuka, Y.; Midorikawa, K.; Matsushige, K.; Kadota, S. Constituents of Chinese propolis and their antiproliferative activities. J. Nat. Prod. 2002, 65, 673-676.
79. Chen, Y.J.; Shiao, M.S.; Hsu, M.L.; Tsai, T.H.; Wang, S.Y. Effect of caffeic acid phenethyl ester, an antioxidant from propolis, on inducing apoptosis in human leukemic HL-60 cells. J. Agric. Food Chem. 2001, 49, 5615-5619.
80. Jin, U.H.; Song, K.H.; Motomura, M.; Suzuki, I.; Gu, Y.H.; Kang, Y.J.; Moon, T.C.; Kim, C.H. Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells. Mol. Cell Biochem. 2008, 310, 43-48.
81. Lee, Y.J.; Kuo, H.C.; Chu, C.Y.; Wang, C.J.; Lin, W.C.; Tseng, T.H. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem. Pharmacol. 2003, 66, 2281-2289.
82. Su, Z.Z.; Lin, J.; Grunberger, D.; Fisher, P.B. Growth suppression and toxicity induced by caffeic acid phenethyl ester (CAPE) in type 5 adenovirus-transformed rat embryo cells correlate directly with transformation progression. Cancer Res. 1994, 54, 1865-1870.
83. Lin, Y.H.; Chiu, J.H.; Tseng, W.S.; Wong, T.T.; Chiou, S.H.; Yen, S.H. Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells. Cancer Chemother Pharmacol. 2006, 57, 525-532.
84. He, Y.J.; Liu, B.H.; Xiang, D.B.; Qiao, Z.Y.; Fu, T.; He, Y.H. Inhibitory effect of caffeic acid phenethyl ester on the growth of SW480 colorectal tumor cells involves beta-catenin associated signaling pathway down-regulation. World J. Gastroenterol. 2006, 12, 4981-4985.
85. Kuo, H.C.; Kuo, W.H.; Lee, Y.J.; Lin, W.L.; Chou, F.P.; Tseng, T.H. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Lett. 2006, 234, 199-208.
86. Wang, D.; Xiang, D.B.; He, Y.J.; Li, Z.P.; Wu, X.H.; Mou, J.H.; Xiao, H.L.; Zhang, Q.H. Effect of caffeic acid phenethyl ester on proliferation and apoptosis of colorectal cancer cells in vitro. World J. Gastroenterol. 2005, 11, 4008-4012.
87. Xiang, D.; Wang, D.; He, Y.; Xie, J.; Zhong, Z.; Li, Z. Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the beta-catenin/T-cell factor signaling. Anticancer Drugs 2006, 17, 753-762.
88. Shigeoka, Y.; Igishi, T.; Matsumoto, S.; Nakanishi, H.; Kodani, M.; Yasuda, K.; Hitsuda, Y.; Shimizu, E. Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition. J. Cancer Res. Clin. Oncol. 2004, 130, 146-152.
89. Weyant, M.J.; Carothers, A.M.; Bertagnolli, M.E.; Bertagnolli, M.M. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin. Cancer Res. 2000, 6, 949-956.
90. Mahmoud, N.N.; Carothers, A.M.; Grunberger, D.; Bilinski, R.T.; Churchill, M.R.; Martucci, C.; Newmark, H.L.; Bertagnolli, M.M. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000, 21, 921-927.
91. Nagaoka, T.; Banskota, A.H.; Tezuka, Y.; Harimaya, Y.; Koizumi, K.; Saiki, I.; Kadota, S. Inhibitory effects of caffeic acid phenethyl ester analogues on experimental lung metastasis of murine colon 26-L5 carcinoma cells. Biol. Pharm. Bull. 2003, 26, 638-641.
92. Borrelli, F.; Izzo, A.A.; Di Carlo, G.; Maffia, P.; Russo, A.; Maiello, F.M.; Capasso, F.; Mascolo, N. Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. Fitoterapia 2002, 73, S38-S43.
93. Carrasco-Legleu, C.E.; Sanchez-Perez, Y.; Marquez-Rosado, L.; Fattel-Fazenda, S.; Arce-Popoca, E.; Hernandez-Garcia, S.; Villa-Trevino, S. A single dose of caffeic acid phenethyl ester prevents initiation in a medium-term rat hepatocarcinogenesis model. World J. Gastroenterol. 2006, 12, 6779-6785.
94. Carrasco-Legleu, C.E.; Marquez-Rosado, L.; Fattel-Fazenda, S.; Arce-Popoca, E.; Perez-Carreon, J.I.; Villa-Trevino, S. Chemoprotective effect of caffeic acid phenethyl ester on promotion in a medium-term rat hepatocarcinogenesis assay. Int. J. Cancer 2004, 108, 488-492.
95. Kudugunti, S.K.; Vad, N.M.; Ekogbo, E.; Moridani, M.Y. Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Investig. New Drugs 2011, 29, 52-62.
96. Liao, H.F.; Chen, Y.Y.; Liu, J.J.; Hsu, M.L.; Shieh, H.J.; Liao, H.J.; Shieh, C.J.; Shiao, M.S.; Chen, Y.J. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J. Agric. Food Chem. 2003, 51, 7907-7912.
97. Orsolic, N.; Knezevic, A.H.; Sver, L.; Terzic, S.; Basic, I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J. Ethnopharmacol. 2004, 94, 307-315.
98. Chung, T.W.; Moon, S.K.; Chang, Y.C.; Ko, J.H.; Lee, Y.C.; Cho, G.; Kim, S.H.; Kim, J.G.; Kim, C.H. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J. 2004, 18, 1670-1681.
99. Horoszewicz, J.S.; Leong, S.S.; Chu, T.M.; Wajsman, Z.L.; Friedman, M.; Papsidero, L.; Kim, U.; Chai, L.S.; Kakati, S.; Arya, S.K., et al. The LNCaP cell line-A new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980, 37, 115-132.
100. Chuu, C.P.; Kokontis, J.M.; Hiipakka, R.A.; Liao, S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 2007, 14, 543-553.
101. Stone, K.R.; Mickey, D.D.; Wunderli, H.; Mickey, G.H.; Paulson, D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978, 21, 274-281.
102. Kaighn, M.E.; Narayan, K.S.; Ohnuki, Y.; Lechner, J.F.; Jones, L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17, 16-23.
103. Kokontis, J.; Takakura, K.; Hay, N.; Liao, S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994, 54, 1566-1573.
104. Kokontis, J.M.; Hay, N.; Liao, S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-Independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 1998, 12, 941-953.
105. Kokontis, J.M.; Hsu, S.; Chuu, C.P.; Dang, M.; Fukuchi, J.; Hiipakka, R.A.; Liao, S. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005, 65, 287-298.
106. Hiipakka, R.A.; Zhang, H.Z.; Dai, W.; Dai, Q.; Liao, S. Structure-Activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem. Pharmacol. 2002, 63, 1165-1176.
107. Wang, L.C.; Chu, K.H.; Liang, Y.C.; Lin, Y.L.; Chiang, B.L. Caffeic acid phenethyl ester inhibits nuclear factor-kappaB and protein kinase B signalling pathways and induces caspase-3 expression in primary human CD4+ T cells. Clin. Exp. Immunol. 2010, 160, 223-232.
108. Ho, H.C.; Hsu, S.L.; Ting, C.T.; Kuo, C.Y.; Yang, V.C. Caffeic acid phenethyl ester inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using a local delivery system. Cell. Mol. Biol. (Noisy-le-grand) 2009, 55, OL1161-OL1167.
109. Cross, D.A.; Alessi, D.R.; Cohen, P.; Andjelkovich, M.; Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378, 785-789.
110. Liang, J.; Slingerland, J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2, 339-345.
111. Alao, J.P. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol. Cancer 2007, 6, 24.
112. Brunet, A.; Park, J.; Tran, H.; Hu, L.S.; Hemmings, B.A.; Greenberg, M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 2001, 21, 952-965.
113. Gu, Y.; Rosenblatt, J.; Morgan, D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992, 11, 3995-4005.
114. Morrison, D.K.; Heidecker, G.; Rapp, U.R.; Copeland, T.D. Identification of the major phosphorylation sites of the Raf-1 kinase. J. Biol. Chem. 1993, 268, 17309-17316.
115. Taniguchi, C.M.; Emanuelli, B.; Kahn, C.R. Critical nodes in signalling pathways: Insights into insulin action. Nat. Rev. Mol. Cell. Biol. 2006, 7, 85-96.
116. Dudek, H.; Datta, S.R.; Franke, T.F.; Birnbaum, M.J.; Yao, R.; Cooper, G.M.; Segal, R.A.; Kaplan, D.R.; Greenberg, M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275, 661-665.
117. Alessi, D.R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15, 6541-6551.
118. Rommel, C.; Bodine, S.C.; Clarke, B.A.; Rossman, R.; Nunez, L.; Stitt, T.N.; Yancopoulos, G.D.; Glass, D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3, 1009-1013.
119. Duan, C.; Liimatta, M.B.; Bottum, O.L. Insulin-Like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J. Biol. Chem. 1999, 274, 37147-37153.
120. Celli, N.; Dragani, L.K.; Murzilli, S.; Pagliani, T.; Poggi, A. In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis. J. Agric. Food Chem. 2007, 55, 3398-3407.
121. Wang, X.; Pang, J.; Maffucci, J.A.; Pade, D.S.; Newman, R.A.; Kerwin, S.M.; Bowman, P.D.; Stavchansky, S. Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. Biopharm. Drug Dispos. 2009, 30, 221-228.
122. Akyol, S.; Ginis, Z.; Armutcu, F.; Ozturk, G.; Yigitoglu, M.R.; Akyol, O. The potential usage of caffeic acid phenethyl ester (CAPE) against chemotherapy-induced and radiotherapy-induced toxicity. Cell. Biochem. Funct. 2012, 30, 438-443.
123. Yagmurca, M.; Erdogan, H.; Iraz, M.; Songur, A.; Ucar, M.; Fadillioglu, E. Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats. Clin. Chim. Acta 2004, 348, 27-34.
124. Fadillioglu, E.; Oztas, E.; Erdogan, H.; Yagmurca, M.; Sogut, S.; Ucar, M.; Irmak, M.K. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J. Appl. Toxicol. 2004, 24, 47-52.
125. Irmak, M.K.; Fadillioglu, E.; Sogut, S.; Erdogan, H.; Gulec, M.; Ozer, M.; Yagmurca, M.; Gozukara, M.E. Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfusion injury in rat brain. Cell. Biochem. Funct. 2003, 21, 283-289.
126. Iraz, M.; Ozerol, E.; Gulec, M.; Tasdemir, S.; Idiz, N.; Fadillioglu, E.; Naziroglu, M.; Akyol, O. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. Cell. Biochem. Funct. 2006, 24, 357-361.
127. Yilmaz, H.R.; Sogut, S.; Ozyurt, B.; Ozugurlu, F.; Sahin, S.; Isik, B.; Uz, E.; Ozyurt, H. The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol. Ind. Health 2005, 21, 67-73.
128. Oktem, F.; Yilmaz, H.R.; Ozguner, F.; Olgar, S.; Ayata, A.; Uzare, E.; Uz, E. Methotrexate-induced renal oxidative stress in rats: The role of a novel antioxidant caffeic acid phenethyl ester. Toxicol. Ind. Health 2006, 22, 241-247.
129. Ozyurt, H.; Sogut, S.; Yildirim, Z.; Kart, L.; Iraz, M.; Armutcu, F.; Temel, I.; Ozen, S.; Uzun, A.; Akyol, O. Inhibitory effect of caffeic acid phenethyl ester on bleomycine-induced lung fibrosis in rats. Clin. Chim. Acta 2004, 339, 65-75.
130. Albukhari, A.A.; Gashlan, H.M.; El-Beshbishy, H.A.; Nagy, A.A.; Abdel-Naim, A.B. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats. Food Chem. Toxicol. 2009, 47, 1689-1695.
131. Yildiz, O.G.; Soyuer, S.; Saraymen, R.; Eroglu, C. Protective effects of caffeic acid phenethyl ester on radiatio n induced lung injury in rats. Clin. Invest. Med. 2008, 31, E242-E247.
132. Chen, Y.J.; Liao, H.F.; Tsai, T.H.; Wang, S.Y.; Shiao, M.S. Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 1252-1261.